New CIDP drug shows promise in early trial
NCT ID NCT04658472
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested a drug called SAR445088 in 98 adults with CIDP, a nerve disorder causing weakness and numbness. The trial looked at how well the drug works in people who are on standard treatment, those who don't respond to it, and those who haven't tried it yet. Researchers measured improvements in disability scores and monitored safety over 24 weeks, with a longer safety follow-up for some participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAR445088 (a drug given intravenously or under the skin)
What this could lead to
If successful, this could point toward a new treatment option for people with CIDP, especially those who don't respond to current therapies.
What could go wrong
This is an early-phase, proof-of-concept study with a small number of participants. The drug may not prove effective or safe in larger trials, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Site Number : 8400005
New York, New York, 10032, United States
-
Investigational Site Number : 1240001
Gatineau, Quebec, J8Y 1W2, Canada
-
Investigational Site Number : 1240002
Québec, G1J 1Z4, Canada
-
Investigational Site Number : 1560001
Shanghai, 200040, China
-
Investigational Site Number : 1560002
Fuzhou, 350001, China
-
Investigational Site Number : 1560004
Wuhan, 430030, China
-
Investigational Site Number : 2500001
Marseille, 13385, France
-
Investigational Site Number : 2500002
Nice, 06002, France
-
Investigational Site Number : 2500003
Bordeaux, France
-
Investigational Site Number : 2500004
Garches, 92380, France
-
Investigational Site Number : 2500005
Le Kremlin-Bicêtre, 94275, France
-
Investigational Site Number : 2760001
Düsseldorf, 40225, Germany
-
Investigational Site Number : 2760002
Göttingen, 37075, Germany
-
Investigational Site Number : 2760003
Essen, 45147, Germany
-
Investigational Site Number : 2760004
Tübingen, 72076, Germany
-
Investigational Site Number : 3800001
Milan, 20132, Italy
-
Investigational Site Number : 3800002
Rome, Lazio, 00168, Italy
-
Investigational Site Number : 3800003
Genova, 16132, Italy
-
Investigational Site Number : 3800005
Rozzano, Milano, 20089, Italy
-
Investigational Site Number : 5280001
Amsterdam, 1105AZ, Netherlands
-
Investigational Site Number : 5280002
Utrecht, 3584 CX, Netherlands
-
Investigational Site Number : 6160001
Lublin, Lublin Voivodeship, 20-954, Poland
-
Investigational Site Number : 6880001
Belgrade, 11000, Serbia
-
Investigational Site Number : 6880002
Belgrade, 11000, Serbia
-
Investigational Site Number : 6880003
Niš, 18000, Serbia
-
Investigational Site Number : 7240001
Barcelona, Barcelona [Barcelona], 08041, Spain
-
Investigational Site Number : 7240002
Barcelona, Barcelona [Barcelona], 08035, Spain
-
Investigational Site Number : 7240003
Valencia, 46026, Spain
-
The University of Kansas Clinical Research Center Site Number : 8400003
Fairway, Kansas, 66205, United States
-
University of California Irvine Site Number : 8400002
Orange, California, 92868, United States
-
University of Minnesota Site Number : 8400006
Minneapolis, Minnesota, 55414, United States
-
University of Southern California Site Number : 8400004
Los Angeles, California, 90033, United States